Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1589 results found

2022 ∙ Huang, Y. Z. Kuan, C. C.

Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Pipitone, G. Rindi, L. V. Petrosillo, N. Foti, N. A. M. Caci, G. Iaria, C. Donno, D. R. Boumis, E. Paviglianiti, G. Taglietti, F.

Vaccine-Induced Subacute Thyroiditis (De Quervain's) after mRNA Vaccine against SARS-CoV-2: A Case Report and Systematic Review

  • Adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Korang, S. K. von Rohden, E. Veroniki, A. A. Ong, G. Ngalamika, O. Siddiqui, F. Juul, S. Nielsen, E. E. Feinberg, J. B. Petersen, J. J. Legart, C. Kokogho, A. Maagaard, M. Klingenberg, S. Thabane, L. Bardach, A. Ciapponi, A. Thomsen, A. R. Jakobsen, J. C. Gluud, C.

Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2022 ∙ Cortés-Sarabia, K. Gutiérrez-Torres, M. Mendoza-Renteria, E. M. Leyva-Vázquez, M. A. Vences-Velázquez, A. Hernández-Sotelo, D. Beltrán-Anaya, F. O. Del Moral-Hernández, O. Illades-Aguiar, B.

Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Martinez-Reviejo, R. Tejada, S. Adebanjo, G. A. R. Chello, C. Machado, M. C. Parisella, F. R. Campins, M. Tammaro, A. Rello, J.

Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights

  • Adults
  • Older adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Nanishi, E. Levy, O. Ozonoff, A.

Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Paybast, S. Emami, A. Baghalha, F. Naser Moghadasi, A.

Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?

  • Adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Romate, J. Rajkumar, E. Gopi, A. Abraham, J. Rages, J. Lakshmi, R. Jesline, J. Bhogle, S.

What Contributes to COVID-19 Vaccine Hesitancy? A Systematic Review of the Psychological Factors Associated with COVID-19 Vaccine Hesitancy

  • All age groups
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2022 ∙ Galanis, Petros Vraka, Irene Siskou, Olga Konstantakopoulou, Olympia Katsiroumpa, Aglaia Kaitelidou, Daphne

Willingness, refusal and influential factors of parents to vaccinate their children against the COVID-19: A systematic review and meta-analysis

  • Parents/caregivers
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2022 ∙ SAGE

Meeting of the Strategic Advisory Group of Experts on Immunization, October 2022: conclusions and recommendations

  • Meeting report
  • Mpox
  • RSV (Respiratory syncytial virus)
  • COVID-19
  • Poliomyelitis
  • Ebola
Download:
Loading...